An analysis of the phase III SOLO1 trial examined safety signals with olaparib maintenance therapy for women with newly diagnosed advanced ovarian cancer and a BRCA mutation.
Researchers analyzed recurrence and survival outcomes for clear cell ovarian carcinoma in the JGOG3017/GCIG trial.
A phase II trial showed that the addition of nintedanib to neoadjuvant chemotherapy did not benefit patients with advanced epithelial ovarian cancer.
Researchers tested maintenance therapy with rucaparib in a phase III trial of patients with recurrent epithelial ovarian cancer who experienced response to platinum-based chemotherapy.
The EWOC-1 trial looked at single-agent carboplatin in vulnerable, elderly patients with stage III/IV epithelial ovarian cancer vs weekly or every 3 weeks carboplatin/paclitaxel.
Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.
This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.
The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab.
The results come from a survey administered to physician members of the Society of Gynecologic Oncology.
In this study from Johns Hopkins, it was found that women with ovarian cancer had better outcomes after the implementation of the Affordable Care Act.